UK firm GSK to pay $2.2bn over Zantac cancer claims
- UK firm GSK agrees to pay $2.2 billion to settle claims that its heartburn drug Zantac caused cancer, involving around 80,000 claimants in the US.
- GSK will also pay $70 million to settle a whistleblower complaint claiming it concealed Zantac's cancer risks from the US government.
- The settlements, which do not include an admission of wrongdoing, aim to address financial uncertainty from ongoing litigation.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left0Leaning Right3Center6Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage